A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice (NCT05637112)
ASTER: Anifrolumab Study for Treatment Effectiveness in the Real World Multi-National, Observational, Post-Launch Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice
🩺 Plain-English Summary (8th-Grade Level)
Anifrolumab Study of Treatment Effectiveness in the Real World (ASTER) study will collect real world data to obtain a good understanding of the (sustained) clinical effect and patient quality of life outcomes among diagnosed SLE patients who initiate anifrolumab treatment. ASTER will generate critical real-world evidence on the benefits of adding anifrolumab to standard of care treatment for SLE in routine clinical practice, to inform physicians, payers and patients.
Who can join: Review the eligibility criteria below.
Location: Research Site — Innsbruck, Tyrol
Age range: 18 Years to 130 Years
🧪 Interventions in This Study
- None (Observational study) (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (79 Sites)
Showing the first 25 of 79 sites.
- Research Site — Innsbruck, Tyrol
- Research Site — Linz, Upper Austria
- Research Site — Vienna,
- Research Site — Liège, Li Ge
- Research Site — Aalst, Oost-Vlaanderen
- Research Site — Bruges, West Flanders
- Research Site — Leuven,
- Research Site — Calgary, Alberta
- Research Site — Winnipeg, Manitoba
- Research Site — Hamilton, Ontario
- Research Site — Orillia, Ontario
- Research Site — Toronto, Ontario
- Research Site — Rimouski, Quebec
- Research Site — Sherbrooke, Quebec
- Research Site — Ste-Foy, Quebec
- Research Site — Nice, Alpes-Maritimes
- Research Site — Clermont-Ferrand, Auvergne-Rh ne-Alpes
- Research Site — Strasbourg, Bas-Rhin
- Research Site — Finist Re, Brest Cedex
- Research Site — Dijon, C te-d'Or
- Research Site — Bordeaux, Gironde
- Research Site — Grenoble, Is Re
- Research Site — Saint-Denis, La R Union
- Research Site — Nantes, Loire-Atlantique
- Research Site — Bouches-du-Rh Ne, Lyon
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Systemic Lupus Erythematosus
- A Study of Obexelimab in Patients With Systemic Lupus Erythematosus — Peoria, Arizona
- A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus — Anniston, Alabama
- REACH (Restore Energy, Activity Can Help) Lupus Study — Boston, Massachusetts
- Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus — Birmingham, Alabama
- A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) — Birmingham, Alabama
Explore by condition: All Systemic Lupus Erythematosus clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.